Pharmacology Update: Suzetrigine: A Novel NaV1.8 Sodium Channel Inhibitor for Acute Pain Management

Supriya Peshin, Claudia Villa Celi, Saima Rashid, Asti Rego, Steven J. Baumrucker, Department of Internal Medicine, Norton Community Hospital, Department of Internal Medicine, Capital Health, New York, Supportive Care, Moffitt Cancer Center, Department of Palliative Medicine, Ballad Health System, Johnson City

American Journal of Hospice and Palliative Medicine®

Published online on July 02, 2025

Abstract

American Journal of Hospice and Palliative Medicine®, Ahead of Print.
Suzetrigine (formerly known as VX-548) is a novel sodium channel inhibitor that selectively targets NaV1.8, a key mediator in pain signal transmission, particularly in peripheral nociceptive neurons. This mechanism distinguishes suzetrigine from ...